NEW YORK (GenomeWeb News) — Fluidigm said today that Cancer Research UK's Centre for Genetic Epidemiology, University of Cambridge, will use its EP1 system to conduct cancer research and disease-association studies.
The center will use the integrated fluidic circuit-based high throughput genotyping system to identify and verify genetic variants that underlie susceptibility to various cancers, including colorectal, prostate, melanoma, breast, and ovarian. The research will take place at the University's Strangeways Research Laboratory.
The company said that the center has successfully completed validation experiments on the EP1 system using real samples and it now will use it in large genotyping studies.
The system includes the IFC controller, Stand-Alone Thermal Cycler, and End Point Reader, and it can provide over 27,000 genotypes per day.
Financial terms of the purchase were not released.